Patients with migraine have the option of an anti-CGRP that is proven to reduce monthly migraine days
Aimovig® (erenumab-aooe) is indicated for the preventive treatment of migraine in adults
Meet Dayna, age 36
Before Aimovig®
Dayna had ≈ 8-12 monthly migraine days
With Aimovig®
Dayna experienced ≥50% reduction in monthly migraine days, with some weeks migraine-free, which has made a real difference for Dayna and the time she spends with those around her.
Aimovig® made a real difference in Dayna’s life. If you have patients like Dayna, don’t wait to see what Aimovig® can do for them.
Learn what more migraine-free days can mean for your patients
Individual results may vary.
Please see Aimovig® full Prescribing Information
IMPORTANT SAFETY INFORMATION
Contraindication: Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.
Hypersensitivity Reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe reaction occurs, discontinue Aimovig® and initiate appropriate therapy.
Constipation with Serious Complications: Constipation with serious complications has been reported following the use of Aimovig® in the postmarketing setting. There were cases that required hospitalization, including cases where surgery was necessary. The onset of constipation was reported after the first dose in a majority of these cases, but patients also reported later on in treatment. Aimovig® was discontinued in most reported cases. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies.
Monitor patients treated with Aimovig® for severe constipation and manage as clinically appropriate. Concurrent use of medications associated with decreased gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications.
Adverse Reactions: The most common adverse reactions in clinical studies (≥ 3% of Aimovig®-treated patients and more often than placebo) were injection site reactions and constipation.
© 2019 Amgen Inc. All rights reserved. USA-334-83291
